Printer Friendly

Evaluating a Novel Drug for Lymphoma

Lymphoma is one of the most common cancers of dogs, accounting for an estimated 25 percent of all canine cancers. more than 8 percent of dogs die of the disease within 2 years because chemoresistance develops. Although all types of dogs can be affected, certain breeds, such as Boxers, rottweilers, Golden Retrievers and Cocker Spaniels, appear to be at greater risk. The researchers will investigate a modified antibody (IMMU-114) that effectively kills canine lymphoma cells but does not appear to result in serious side effects when administered to healthy dogs. They will work to find the best dosage and evaluate its safety and effectiveness in dogs with B-cell lymphoma. If successful, this research might provide a new treatment option for owners of dogs that develop this type of lymphoma. This antibody might also be effective in the treatment of malignant histiocytosis, a cancer commonly found in Bernese mountain Dogs. Therefore, a secondary aim of this project will be to conduct preliminary studies to determine if IMMU-114 could be effective in treating this aggressive disease.

Dr. Barbara Biller, Colorado State University

Co-sponsors: Flat-Coated Retriever Foundation; Trudy Lanman; Golden Retriever Foundation; Dr. & Mrs. Martin V. Haspel; The Aura McConnell Foundation, Inc.; Anonymous, for Pixel, Princess & Sage; The Dixie Foundation, Inc.; Rainier Agility Team; The American German Shepherd Dog Charitable Foundation, Inc.; The Bearded Collie Club of America Charitable Trust; Bernese Mountain Dog Club of America (BMDCA); Anonymous; Bob Gain and Alex Redman, in memory of Parker Gain